Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | HRH2 | P25021 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13654942 | 0.88 | CHRM3 (0.42) | L3MBTL1CHRM3CHRM2NPC1RAB9A | |
| SCHEMBL404609 | 0.88 | CHRM3 (0.42) | L3MBTL1CHRM3CHRM2NPC1RAB9A | |
| SCHEMBL13654913 | 0.83 | CHRM2 (0.42) | CHRM3CHRM2 | |
| SCHEMBL403192 | 0.83 | CHRM2 (0.42) | CHRM3CHRM2 | |
| SCHEMBL436956 | 0.83 | CHRM2 (0.42) | CHRM3CHRM2 | |
| SCHEMBL1109142 | 0.80 | DRD2 (0.42) | L3MBTL1CHRM3CHRM2NPC1RAB9A | |
| SCHEMBL1109460 | 0.75 | ALDH1A1 (0.41) | L3MBTL1CHRM3CHRM2NPC1RAB9A | |
| SCHEMBL13659485 | 0.75 | ALDH1A1 (0.41) | L3MBTL1CHRM3CHRM2NPC1RAB9A | |
| SCHEMBL1912207 | 0.75 | ALDH1A1 (0.41) | L3MBTL1CHRM3CHRM2NPC1RAB9A | |
| SCHEMBL400311 | 0.74 | L3MBTL1 (0.40) | L3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7358359-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2008-04-15 | — | — | US | disclosed |
| US-20060154988-A1 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154988-A1 | Antibacterial agents | MRPL21, SI, PGLS | L3MBTL1 2665/4885CHRM3 4831/4885CHRM2 4835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.